Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,948 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00081874 | RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT01242930 | Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma | completed | Phase 2 | 13 | Geron CorporationINDUSTRY | 1 | Jun 17, 2026 |
| NCT03839459 | Denosumab for Smoldering Multiple Myeloma | completed | Phase 2 | 20 | University of RochesterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04737265 | Pilot Study of an NTproBNP Guided Strategy of Cardioprotection(NTproBNP-Guide) | completed | Phase 1 / Phase 2 | 108 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT02232516 | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | completed | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04113226 | Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma(Relyage) | completed | Phase 2 | 1 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05978739 | Evaluating Different Doses of Orelabrutinib in MCL | completed | Phase 2 | 40 | InnoCare Pharma Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT02242097 | Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma | completed | Phase 2 | 37 | Northwestern UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT03505554 | A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma(CRU3) | completed | Phase 2 | 9 | University of Milano BicoccaOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT02997761 | Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia | completed | Phase 2 | 19 | University of California, DavisOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT03494179 | A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) | completed | Phase 1 / Phase 2 | 106 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT00107198 | Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease | completed | Phase 2 | 188 | Children's Oncology GroupNETWORK | 6 | Jun 5, 2026 | clinicaltrials |
| NCT01702831 | Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance(BuMelMCRN001) | completed | Phase 2 | 78 | University Health Network, TorontoOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03196830 | CAR-T for R/R B-NHL | completed | Phase 2 | 168 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04539444 | A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma | completed | Phase 2 | 18 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05322330 | Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT02220985 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | completed | Phase 2 | 84 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03434730 | Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation | completed | Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT00690560 | Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma | completed | Phase 2 | 30 | Centre Antoine LacassagneOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT01476410 | Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma | completed | Phase 2 | 49 | Northwestern UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03789097 | Vaccination With Flt3L, Radiation, and Poly-ICLC | completed | Phase 1 / Phase 2 | 17 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05032820 | Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma | completed | Phase 2 | 40 | Medical College of WisconsinOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT02362997 | Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL | completed | Phase 2 | 82 | Dana-Farber Cancer InstituteOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT01053949 | IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma(IFM2009-02) | completed | Phase 2 | 84 | University Hospital, LilleOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT01222286 | Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma(KIRMONO) | completed | Phase 2 | 30 | Innate PharmaINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT01009840 | IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients | completed | Phase 2 | 30 | Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY | 2 | May 13, 2026 | clinicaltrials |
| NCT02362035 | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies(KEYNOTE145) | completed | Phase 1 / Phase 2 | 161 | Acerta Pharma BVINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT05169658 | Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma | completed | Phase 2 | 42 | University of WashingtonOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT01208896 | Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma(RITALLO) | completed | Phase 2 | 32 | University Hospital, BordeauxOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04731844 | Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer | completed | Phase 2 | 30 | University of RochesterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03413800 | Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant | completed | Phase 2 | 10 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03927105 | Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma | completed | Phase 2 | 4 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05532722 | ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) | completed | Phase 1 / Phase 2 | 21 | Abcuro, Inc.INDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT03477539 | Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma | completed | Phase 2 | 49 | Mayo ClinicOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03580564 | An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma | completed | Phase 2 | 109 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT05064358 | Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma(DREAMM 14) | completed | Phase 2 | 177 | GlaxoSmithKlineINDUSTRY | 18 | May 5, 2026 | clinicaltrials |
| NCT03035331 | Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 11 | Mayo ClinicOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04083534 | First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 43 | Regeneron PharmaceuticalsINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT03902184 | IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma(TELLOMAK) | completed | Phase 2 | 170 | Innate PharmaINDUSTRY | 8 | Apr 29, 2026 | clinicaltrials |
| NCT05388123 | Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia | completed | Phase 2 | 15 | Scripps HealthOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT02316106 | A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma | completed | Phase 2 | 123 | Janssen Research & Development, LLCINDUSTRY | 11 | Apr 23, 2026 | clinicaltrials |
| NCT02661542 | Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 106 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT02433795 | Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) | completed | Phase 2 | 27 | Seoul National University HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01816971 | Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 76 | University of ChicagoOTHER | 2 | Apr 21, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT03623373 | Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma | completed | Phase 2 | 13 | Washington University School of MedicineOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05189093 | Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma | completed | Phase 1 / Phase 2 | 48 | Hangzhou Hanx Biopharmaceuticals, Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03341520 | Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma(GAZAI) | completed | Phase 2 | 89 | Heidelberg UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 18, 2026source: clinicaltrials